Literature DB >> 10087940

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.

J Kuipers1, J W Vaandrager, D O Weghuis, P L Pearson, J Scheres, H M Lokhorst, H Clevers, B J Bast.   

Abstract

In many B-cell malignancies, 14q32.3 chromosomal rearrangements involving the immunoglobulin heavy chain (IgH) locus have been shown to be pathognomonic for the disease. Although in myeloma heterogeneous and complex karyotypes are found, 14q32.3 translocations are prominent. However, owing to the telomeric position of the IgH locus, 14q32.3 translocations may be easily missed. We established fluorescence in situ hybridization (FISH) assays on chromosomes and DNA fibers to determine both the occurrence of 14q32.3 rearrangements in myeloma cell lines and the precise localization of the breakpoints in the IgH locus. Our results show that 14q32.3 chromosomal rearrangements are present in almost every myeloma cell line analyzed (17 of 19, 89%). Breakpoint analysis of the lines harboring one or more 14q32.3 rearrangements with the use of fiber-FISH revealed the involvement of switch regions in the IgH locus in 11 of 17 cell lines. Remarkably, pseudogamma genes without switch regions were involved in 3 of 17 cell lines, all derived from IgA myelomas. Three of 17 cell lines contained breakpoints outside a switch or immunoglobulin heavy chain constant region. The almost ubiquitous presence of 14q32.3 rearrangements suggests an obligatory role in the development of myeloma. The high incidence of breakpoints involving switch regions indicates an oncogenic event in a late stage of B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087940     DOI: 10.1016/s0165-4608(98)00157-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.

Authors:  A Kühnemund; P Liebisch; K Bauchmüller; A zur Hausen; H Veelken; R Wäsch; M Engelhardt
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-18       Impact factor: 4.553

2.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

3.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Authors:  Patrick W B Derksen; Esther Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

4.  Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation.

Authors:  Mariko Yabe; Neval Ozkaya; Daphne de Jong; Umut Aypar; M Stella Ritorto; Ellis Barbé; Iris H C Miedema; Filiz Sen; Jessica R Chapman; Heather J Landau; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2021-07-01       Impact factor: 6.298

5.  Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.

Authors:  Tao Yu; Chunxia Qiao; Ming Lv; Luqun Tang
Journal:  BMC Biotechnol       Date:  2019-05-22       Impact factor: 2.563

6.  Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Authors:  Marije B Overdijk; Sandra Verploegen; Marijn Bögels; Marjolein van Egmond; Jeroen J Lammerts van Bueren; Tuna Mutis; Richard W J Groen; Esther Breij; Anton C M Martens; Wim K Bleeker; Paul W H I Parren
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3).

Authors:  Theodora Malli; Melanie Rammer; Sabrina Haslinger; Jonathan Burghofer; Sonja Burgstaller; Hans-Christian Boesmueller; Renate Marschon; Wolfgang Kranewitter; Martin Erdel; Sabine Deutschbauer; Gerald Webersinke
Journal:  Mol Cytogenet       Date:  2018-01-11       Impact factor: 2.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.